difficult
control
gener
immunosuppress
therapi
includ
corticosteroid
due
unfavor
effect
viral
replic
studi
suggest
excess
activ
innat
immun
ifv
respons
sever
patholog
studi
focus
signal
adaptor
known
regul
innat
immun
activ
multipl
innat
sensor
protein
investig
role
antiifv
defens
lung
pathogenesi
mous
model
recapitul
sever
influenza
pneumonia
ard
found
influenza
pneumonia
dramat
attenu
mice
show
improv
mortal
reduc
inflammatori
cytokin
chemokin
infect
lung
howev
viral
clearanc
typei
interferon
product
develop
antivir
b
cell
immun
compromis
defici
syk
dc
macrophag
show
impair
cytokin
typei
interferon
product
respons
ifv
vitro
indic
possibl
role
pathway
dc
excess
inflamm
ifvinfect
lung
therefor
inhibit
pathway
ideal
therapeut
target
sever
influenza
pneumonia
without
affect
viral
clearanc
host
innat
immun
system
includ
macrophag
dendrit
cell
dc
secret
inflammatori
cytokineschemokin
tnf
play
crucial
role
pathogenesi
ard
therefor
inhibit
cytokinechemokin
product
via
target
host
innat
immun
system
may
lead
develop
effect
treatment
option
ard
caspas
recruit
domain
famili
member
adaptor
protein
deliv
b
activ
signal
multipl
innat
sensor
protein
wide
array
ctype
lectin
clr
immunoglobulin
ig
superfamili
receptor
coupl
immunoreceptor
tyrosinebas
activ
motif
itam
well
cytoplasm
rna
sensor
rigi
dna
sensor
sever
line
evid
impli
role
innat
activ
pathway
influenza
pathogenesi
immun
clr
dendrit
cellspecif
grab
nonintegrin
dcsign
cytoplasm
itamlik
sequenc
shown
bind
influenza
viru
addit
found
requir
product
inflammatori
cytokin
infect
rna
virus
vesicular
stomat
viru
encephalomyocard
viru
regul
b
signal
rigi
howev
role
influenza
pneumonia
well
protect
ifv
yet
elucid
studi
demonstr
role
innat
activ
influenza
pathogenesi
immun
result
show
pathway
involv
fatal
influenza
pneumonia
mediat
inflammatori
cytokinechemokin
product
wherea
dispens
typei
interferon
product
well
develop
antivir
acquir
immun
therefor
inhibit
pathway
may
repres
ideal
target
treatment
sever
influenza
pneumonia
without
affect
viral
clearanc
adapt
ifv
strain
show
similar
lung
patholog
human
ard
intratrach
infect
wildtyp
wt
mice
lethal
dose
pfumous
determin
whether
innat
immun
respons
contribut
sever
influenza
pneumonia
observ
wt
mice
appear
visibl
ill
ruffl
fur
reduc
oral
intak
day
infect
wherea
mice
appear
activ
wt
mice
consist
activ
final
surviv
rate
day
infect
dramat
improv
mice
compar
wt
mice
fig
histopatholog
analysi
ifvinfect
lung
day
reveal
lung
inflamm
obviou
day
wt
mice
much
less
sever
mice
fig
given
inflammatori
cytokineschemokin
link
lung
damag
sever
influenza
pneumonia
analyz
infiltr
cell
cytokinechemokin
level
bronchoalveolar
lavag
fluid
balf
collect
ifvinfect
lung
wt
mice
consist
patholog
data
number
balf
cell
significantli
fewer
lung
mice
wt
mice
day
mark
decreas
number
cell
neutrophil
fig
two
main
infiltr
subpopul
time
point
supplementari
fig
howev
number
b
cell
nk
cell
macrophag
cdc
pdc
significantli
affect
defici
balf
level
inflammatori
cytokin
chemokin
ie
report
contribut
lung
patholog
peak
day
consider
lower
mice
wt
mice
fig
howev
reduct
cytokinechemokin
level
evid
day
indic
innat
respons
control
cytokinechemokin
product
earli
time
point
ifv
infect
influenc
subsequ
inflammatori
cell
recruit
lung
patholog
later
time
point
collect
loss
attenu
sever
influenza
pneumonia
improv
host
mortal
defici
compromis
antivir
protect
immun
activ
innat
immun
respons
ifv
regul
antivir
protect
immun
evalu
impact
defici
antiifv
protect
first
analyz
viral
burden
ifvinfect
lung
wt
mice
notabl
found
defici
increas
viru
titer
amount
viral
rna
lung
instead
significantli
acceler
viral
clearanc
later
stage
day
infect
fig
typei
interferon
primari
factor
induc
host
resist
ifv
contrast
cytokinechemokin
product
defici
significantli
affect
product
ifvinfect
lung
fig
type
ii
interferon
essenti
viral
clearanc
presenc
ifv
infect
amelior
sever
inflamm
lung
injuri
product
significantli
lung
mice
wt
mice
day
day
fig
thu
increas
might
contribut
improv
lung
patholog
mice
moreov
express
encod
ifnrespons
gene
significantli
impair
mice
day
fig
albeit
signific
reduct
seen
either
type
type
ii
interferon
suggest
synergist
signal
interferon
variou
cytokineschemokin
requir
higher
express
earli
phase
infect
next
examin
induct
virusspecif
cell
use
b
tetram
coupl
viral
nuclear
protein
np
deriv
peptid
np
percentag
npspecif
cell
drain
lymph
node
lung
day
compar
wt
mice
fig
evalu
impact
defici
acquir
immun
ifv
wt
mice
immun
subleth
dose
ld
strain
rechalleng
high
lethal
dose
ld
week
found
defici
alter
viral
clearanc
challeng
fig
next
assess
induct
humor
cellular
acquir
immun
ifv
mice
reinfect
wt
mice
day
first
infect
repres
second
infect
analyz
product
virusspecif
antibodi
well
develop
virusspecif
cell
day
second
infect
found
defici
affect
neither
product
virusspecif
igg
serum
virusspecif
iga
lung
mucosa
fig
addit
defici
affect
respons
splenic
cell
specif
np
antigen
epitop
np
fig
collect
pathway
dispens
induct
protect
immun
primari
secondari
ifv
infect
defici
even
improv
primari
viral
clearanc
upon
lethaldos
infect
probabl
improv
lung
damag
elev
product
defici
impair
inflammatori
cytokin
typei
interferon
product
dc
macrophag
dc
known
earli
sourc
inflammatori
cytokin
typei
interferon
pulmonari
ifv
infect
examin
whether
requir
product
myeloid
cell
respons
ifv
thioglycolateinduc
periton
macrophag
tgmf
bone
marrowderiv
macrophag
bmmf
alveolar
macrophag
amf
convent
dc
cdc
ligandinduc
plasmacytoid
dc
prepar
wt
mice
brought
contact
vitro
product
measur
produc
tgmf
fig
bmmf
fig
mrna
produc
amf
fig
respons
affect
defici
previous
report
requir
cytokin
respons
oxzymosan
dispens
respons
lp
cdc
supplementari
fig
found
cdc
fig
fig
produc
significantli
lower
level
wt
cell
respons
contrast
product
compromis
cdc
find
suggest
defici
primarili
affect
dc
mf
regard
product
inflammatori
cytokin
respons
ifv
report
pathway
mediat
cytokin
respons
rna
virus
rlh
found
transmit
signal
myeloid
itamcoupl
receptor
via
syk
thu
evalu
contribut
pathway
cdc
produc
significantli
lower
level
wt
cell
respons
fig
e
consist
previou
find
show
respons
rna
virus
mediat
mainli
cdc
pdc
addit
product
impair
cdc
lower
level
cytokin
product
also
observ
cdc
like
due
impair
activ
sever
tlr
ie
sens
viru
nucleic
acid
found
induc
sykdefici
syk
deldel
cdc
produc
significantli
lower
level
inflammatori
cytokin
wt
cell
similar
respons
cdc
wherea
syk
defici
affect
cytokin
product
respons
lp
supplementari
fig
consist
find
treatment
wt
cdc
fig
fig
syk
inhibitor
reduc
product
inflammatori
cytokin
typei
interferon
respons
dosedepend
manner
treatment
reduc
cytokin
respons
oxzymosan
lp
indic
effect
inhibitor
cytokin
express
depend
stimulu
attribut
gener
effect
cytokin
gene
express
supplementari
fig
overal
result
suggest
attenu
influenza
pneumonia
defici
like
attribut
reduc
cytokinechemokin
product
pulmonari
dc
pathway
respons
ifv
shown
activ
innat
immun
system
exacerb
influenza
pneumonia
mice
defici
result
reduct
inflammatori
cytokinechemokin
infiltr
inflammatori
cell
ifvinfect
lung
result
improv
mous
mortal
rate
given
patholog
similar
mous
intratrach
infect
model
influenzaassoci
ard
human
postul
pathway
contribut
exacerb
human
influenza
pneumonia
although
innat
immun
balf
analyz
day
second
infect
f
ifvspecif
adapt
cell
respons
splenocyt
wt
mice
n
per
group
day
infect
e
stimul
vitro
ifv
nucleoprotein
peptid
np
day
cultur
supernat
analyz
product
data
present
mean
sd
triplic
data
repres
three
independ
experi
p
student
ttest
scientif
report
doi
respons
crucial
antifung
acquir
immun
data
show
dispens
antiifv
immun
demonstr
find
defici
alter
viral
burden
elev
induct
antivir
adapt
b
cell
respons
ifvinfect
mice
thu
innat
mechan
independ
pathway
may
play
domin
role
protect
immun
ifv
innat
immun
sensor
ifv
downstream
signal
pathway
well
illustr
studi
defici
result
select
reduct
inflammatori
cytokin
product
cdc
respons
ifv
pattern
impair
observ
cdc
consist
result
previou
report
indic
select
regul
cytokin
respons
rigiipsi
cdc
addit
found
syk
deldel
syk
inhibitortr
cdc
show
pattern
impair
cdc
hand
known
releas
larg
amount
inflammatori
cytokin
typei
interferon
upon
recognit
ifv
defici
affect
neither
cytokin
typei
interferon
respons
howev
syk
defici
similar
cdc
result
select
reduct
inflammatori
cytokin
thu
like
pathway
control
detriment
cytokin
product
pulmonari
dc
upon
acut
influenza
infect
altern
defici
impair
cytokin
product
dc
follow
stimul
sever
tlr
ligand
may
import
examin
whether
pathway
involv
respons
ifv
involv
pathway
impli
presenc
itamcoupl
receptor
sens
ifv
stimul
cytokin
product
dc
report
interact
dcsign
possess
itamlik
hemitam
motif
carbohydr
ifv
hemagglutinin
induc
matur
dc
promot
endocytosi
viru
indic
signalactiv
capac
dcsign
upon
viru
bind
howev
unclear
whether
dcsign
hemitam
capabl
transmit
suffici
signal
produc
inflammatori
cytokin
regard
virus
recognit
dengu
viru
clr
result
increas
vascular
permeabl
due
overproduct
result
fatal
outcom
howev
abil
recogn
ifv
remain
unknown
thu
worth
examin
whether
clr
involv
cytokin
respons
ifv
also
conceiv
damageassoci
molecular
pattern
damp
gener
due
lung
damag
ifv
infect
may
ligand
itamcoupl
receptor
inde
associ
clr
mincl
shown
recogn
compon
ribonucloprotein
releas
dead
cell
conclus
innat
immun
activ
pulmonari
dc
act
exacerb
sever
influenza
pneumonia
dispens
host
protect
ifv
thu
inhibit
pathway
may
repres
promis
therapeut
target
control
pivp
without
affect
viral
clearanc
mice
syk
floxflox
mice
previous
describ
mice
backcross
least
time
onto
mice
mice
purchas
clea
japan
inc
tokyo
japan
anim
hous
specif
pathogenfre
condit
experi
approv
institut
anim
care
use
committe
kitasato
univers
medic
center
anim
treat
accord
regul
anim
experi
kitasato
univers
surgeri
perform
ketamin
hydrochloridexylazin
anesthesia
effort
made
minim
suffer
antibodi
reagent
fluorescein
isothiocyan
fitc
conjug
clone
fitcconjug
clone
fitcconjug
clone
phycoerythrin
pe
conjug
clone
peconjug
antisiglech
clone
biotinconjug
clone
biotinconjug
clone
peridinin
chlorophyl
conjug
clone
conjug
clone
clone
monoclon
antibodi
purchas
biolegend
san
diego
ca
fitcconjug
clone
monoclon
antibodi
peconjug
b
tetram
coupl
viral
npderiv
asnenmetm
peptid
np
asnenmetm
b
restrict
influenza
np
peptid
purchas
mbl
nagoya
japan
syk
inhibitor
iv
bay
purchas
merck
millipor
billerica
lp
escherichia
coli
purchas
sigmaaldrich
st
loui
mo
naclooxid
zymosan
prepar
describ
ifv
infect
mice
mice
anesthet
infect
plaqu
form
unit
pfu
unless
otherwis
indic
mouseadapt
ifv
strain
isotyp
kindli
provid
kitasato
institut
tokyo
japan
intratrach
administr
describ
histolog
whole
lung
collect
day
ifv
infect
paraffin
embed
hematoxylin
eosin
stain
tissu
perform
use
standard
methodolog
bal
carri
describ
previous
brief
trachea
mice
cannul
diamet
polyethylen
cathet
lung
instil
ml
prewarm
pb
contain
mm
edta
follow
retriev
lavag
fluid
aliquot
cell
bal
fluid
balf
count
red
blood
cell
lysi
subject
flow
cytometr
analysi
supernat
balf
subject
multi
cytokinechemokin
express
analysi
cytokin
elisa
cytomix
cytokin
bead
assay
bender
medsystem
vienna
austria
except
measur
verikin
tm
mous
elisa
kit
pbl
interferonsourc
piscataway
nj
cell
cultur
supernat
splenocyt
assay
use
specif
elisa
kit
biolegend
cell
cultur
supernat
tgmf
bmmf
cdc
assay
use
specif
elisa
kit
biolegend
pbl
interferonsourc
measur
perform
triplic
quantit
pcr
qpcr
analysi
cytokin
mrna
total
rna
extract
cell
reliaprep
rna
cell
miniprep
system
promega
madison
wi
cdna
synthes
primescript
rt
reagent
kit
takara
bio
shiga
japan
accord
manufactur
instruct
qpcr
perform
appli
biosystem
fast
real
time
pcr
system
life
technolog
primer
sequenc
follow
mous
forword
ctt
cac
aag
tcg
gag
gct
ta
revers
agt
gca
tca
tcg
ttg
ttc
ata
c
tnf
forword
cta
tgg
ccc
aga
ccc
tca
c
revers
acc
act
agt
tgg
ttg
tct
ttg
viral
copi
number
mice
euthan
intraperiton
administr
sodium
pentobarbit
day
ifv
infect
lung
tissu
homogen
use
gentlemac
dissoci
miltenyi
biotec
rna
extract
isogen
ii
rna
extract
kit
nippon
gene
tokyo
japan
revers
transcript
conduct
primer
aaa
agc
agg
qpcr
preform
primer
specif
np
forward
tgg
tgg
aat
tgg
acg
revers
gca
cca
ttc
tct
cta
tt
use
appli
biosystem
fast
real
time
pcr
system
life
technolog
carlsbad
ca
standard
calibr
curv
qpcr
obtain
stepwis
dilut
clone
np
gene
fragment
known
copi
number
ifv
rechalleng
wt
mice
left
uninfect
infect
intratrach
subleth
dose
pfumous
ld
twentyeight
day
first
infect
mice
challeng
high
lethal
dose
pfumous
ld
two
day
postchalleng
viru
titer
lung
measur
plaqu
assay
mdck
cell
antigenspecif
b
cell
respons
b
cellmedi
humor
respons
measur
virionspecif
immunoglobulin
product
elisa
previous
describ
briefli
elisa
plate
corn
coat
ultrason
influenza
virion
strain
pfu
ml
carbon
buffer
ph
incub
overnight
plate
wash
pb
contain
tween
wako
pure
chemic
industri
serum
balf
collect
mice
day
secondari
infect
serial
dilut
pbstween
contain
skim
milk
appli
onto
virionco
plate
incub
h
room
temperatur
wash
goat
antimous
total
igg
iga
conjug
horseradish
peroxidas
jackson
immunoresearch
baltimor
pike
pa
appli
incub
h
room
temperatur
wash
plate
stain
tmb
substrat
set
biolegend
reaction
termin
h
wako
pure
chemic
industri
absorb
measur
antigenspecif
cell
respons
ifvspecif
cell
respons
measur
viral
npspecif
secret
splenocyt
describ
previous
briefli
splenocyt
extract
mice
secondari
infect
seed
cell
cultur
plate
corn
stimul
gml
np
peptid
day
cultur
supernat
collect
analyz
product
elisa
biolegend
tgmf
prepar
describ
amf
isol
balf
wt
mice
bmmf
cdc
prepar
cultur
bone
marrow
cell
day
medium
wako
pure
chemic
industri
supplement
fetal
bovin
serum
life
technolog
antibiot
iuml
penicillin
gml
streptomycin
sigmaaldrich
contain
mcsf
ngml
peprotech
rocki
hill
nj
gmcsf
ngml
peprotech
human
ngml
peprotech
respect
deriv
cultur
contain
constantli
siglech
plasmacytoid
dc
pdc
irrespect
defici
syk
syk
delet
vitro
cultur
cell
deriv
syk
floxflox
mice
incub
activ
metabolit
tamoxifen
sigmaaldrich
stimul
mfsdc
cell
seed
cultur
plate
corn
incub
overnight
follow
replac
l
serumfre
medium
contain
pfu
multipl
infect
moi
h
incub
unabsorb
virus
remov
cell
incub
h
serumcontain
medium
dc
also
stimul
lp
ngml
naclooxid
zymosan
gml
h
serumcontain
medium
cultur
supernat
assay
elisa
stimul
amf
cell
seed
cultur
plate
corn
stimul
pfu
moi
h
total
rna
extract
qpcr
analysi
cytokin
express
treatment
cell
chemic
syk
inhibitor
wt
dc
incub
bay
h
prior
viru
stimul
cell
viabil
cell
viabil
determin
mt
assay
use
celltit
aqueouson
solut
cell
prolifer
assay
kit
promega
brief
l
mt
solut
ad
cell
plate
vitro
ifv
stimul
plate
incub
h
absorb
nm
measur
use
benchmark
micropl
reader
biorad
hercul
ca
statist
analysi
surviv
curv
gener
kaplanmei
method
statist
analys
perform
use
logrank
test
statist
signific
assess
student
ttest
p
valu
consid
signific
